US 11,053,307 B2
Compounds and methods for treating pain
Darren Schofield, Melbourn (GB); Matthew Alexander Sleeman, Cambridgeshire (GB); Iain Patrick Chessell, Essex (GB); Jonathan Hatcher, Essex (GB); and David Lowe, Royston (GB)
Assigned to MedImmune Limited, Cambridge (GB)
Filed by MedImmune Limited, Cambridge (GB)
Filed on Sep. 17, 2019, as Appl. No. 16/573,192.
Application 16/573,192 is a continuation of application No. 15/849,771, filed on Dec. 21, 2017, granted, now 10,457,728.
Application 15/849,771 is a continuation of application No. 14/612,137, filed on Feb. 2, 2015, granted, now 9,884,911, issued on Feb. 6, 2018.
Claims priority of provisional application 61/934,828, filed on Feb. 2, 2014.
Prior Publication US 2020/0123241 A1, Apr. 23, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/22 (2006.01); C07K 14/715 (2006.01); C07K 14/48 (2006.01); C07K 14/705 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/22 (2013.01) [C07K 14/48 (2013.01); C07K 14/70578 (2013.01); C07K 14/7151 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01); C07K 2319/35 (2013.01)] 24 Claims
 
1. An isolated polynucleotide encoding a binding molecule; wherein the binding molecule comprises an NGF antagonist domain and a TNFα antagonist domain, wherein the NGF antagonist domain comprises an anti-NGF antibody or fragment thereof; wherein the TNFα antagonist domain comprises a soluble, TNFα-binding fragment of TNFR-2; wherein the anti-NGF antibody or fragment thereof comprises a VH domain comprising a set of CDRs HCDR1, HCDR2, HCDR3 and a VL domain comprising a set of CDRs LCDR1, LCDR2 and LCDR3, wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO: 4, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 5, the HCDR3 comprises the amino acid sequence of any one of SEQ ID NOs: 6, 11 or 12, the LCDR1 comprises the amino acid sequence of SEQ ID NO: 8, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 9, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 10; wherein a cysteine is present in the VH domain at the amino acid corresponding to amino acid position 44 of SEQ ID NO: 94; and wherein a cysteine is present in the VL domain at the amino acid corresponding to amino acid position 103 of SEQ ID NO: 95.